hair loss
Conditions
Interventions
Control group:N/A
Androgenetic alopecia group:N/A
Sponsors
Department of Plastic and Reconstructive Surgery, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1)Norwood-Hamilton ?-? and Ludwig ?-? volunteers with androgenetic alopecia. (2) 18-60 years old, medical history more than 1 year; (3) not receiving any alopecia related treatment within 12 weeks before laser treatment. (4) Informed consent: individuals voluntarily participated in this study and signed an informed consent form. (5) complete medical records and clinical data.
Exclusion criteria
Exclusion criteria: (1) Alopecia caused by other causes, including but not limited to syptic alopecia androgenetic alopecia (AGA), epileptic alopecia diffuse alopecia (characterized by diffuse hair loss), alopecia areata hyperplasic (involving pars and occipital hairline), traction alopecia, growth phase alopecia, folliculotropic mycosis (FMF), or thyroid diseases. (2) Subjects with other active skin diseases, scalp diseases, active scalp trauma, etc. that the investigators considered to affect the efficacy or safety study evaluation. Subjects with shaved heads were not included in the study until their hair had regrown and was considered stable by the investigator. (3) Patients who were not suitable for Er:Yag treatment or only Er:Yag treatment according to the judgment of other clinicians. (4) Any previous JAK inhibitor (oral or topical) treatment for any disease indication. (5) Systemic treatment with local immunotherapy AA within the previous 2 months; Intralesional immunosuppressive therapy was used for Plaeod. (6) Use topical preparations on the head or phototherapy within the previous 2 months; Cryotherapy; And other AA treatments. (7) Taking probiotics or prebiotics as intestinal microecological modulators within the past 1 month. (8) Patients with scar constitution; (9) Patients with definite systemic diseases, connective tissue diseases, neoplastic diseases, etc (10) Systemic use of glucocorticoids, antibiotics or immunosuppressants within 4 weeks. (11) Oral anti-androgen or spironolactone drugs in the past 1 month, and AGA treatment in the past 6 months (12) Subjects with current thyroid disease or receiving thyroxine replacement therapy. Subjects with abnormal TSH levels and associated abnormal fT4 or fT3 values at screening or with abnormal TSHfT4 or fT3 values with signs and/or symptoms suggestive of hypothyroidism or hyperthyroidism were excluded. (13) Any live or attenuated live vaccine administered within 4 weeks before the first dose of the study drug. (14) Participants who had participated in any drug or medical device clinical trial within 1 month or 5 drug half-lives, whichever was longer, before screening. (15) Subjects with a history of severe neuropsychiatric disorders. (16) Except for those with malignancy/lymphoproliferation or a history of adequately treated or resected nonmetastatic basal cell carcinoma or squamous cell carcinoma of the skin. (17) Subjects who were positive for specific treponema pallidum or infected with human immunodeficiency virus (HIV) or type or hepatitis C virus. (18) Subjects with a previous history of thrombotic disease. (19) Hemoglobin level 2XULN. Subjects with cirrhosis. eGFR=60mL/min or patients undergoing conventional hemodialysis or peritoneal dialysis. (20) Subjects may have active, latent, or inadequately treated M. tuberculosis infection. (21) Clinically significant infection with a history of 2 or more episodes of band rash or disseminated band scar rash (single episode) within 1 month before baseline, and any infection requiring antimicrobial therapy within 2 weeks of screening. (22) The investigators considered that subjects with a history of alcohol or dr
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| microorganism species;Amount of sebum; | — |
Countries
China
Contacts
Public Contactliu Guangpeng
Shanghai Tenth People's Hospital, Tongji University School of Medicine
Outcome results
None listed